Vaccine maker Biontech plans to achieve significantly more sales with its corona vaccine. The Mainz-based company increased its forecast for the current year from 12.4 billion to 15.9 billion euros. And it could be even more, as current sales forecasts are based on contracts signed on July 21 for the delivery of around 2.2 billion doses of vaccine by the end of the year. “Additional sales are expected under new supply contracts for deliveries in 2021, with the first contracts for 2022 and beyond having already been concluded,” the company said.
Biontech partner Pfizer had already raised its sales forecast for the vaccine at the end of July after the signing of new supply contracts. According to Biontech, a total of three billion cans are now produced by the end of the year. In 2022, it should then reach four billion units. As of July 21, more than a billion doses of vaccine had been delivered to more than 100 regions.
Regarding a possible booster vaccination that would be given with a third syringe, the company said: “Biontech and Pfizer believe that a booster or third dose has the potential to maintain the highest level of protection against all variants currently being tested, including Delta “” In the coming weeks, more precise data from the analysis of ongoing clinical studies are to be published and submitted to regulatory authorities in the United States, European Union (EU) and other countries.
Biontech also released its financial data for the second quarter on Monday. Over the months of April to June, the company put in 5.31 billion euros thanks to the vaccine, against 41.7 million euros in the same period last year. Net profit amounted to 2.79 billion euros after a loss of 88.3 million a year earlier.
Above all, the higher annual forecast was well received in the stock market: Biontech shares climbed 6.5% immediately after the quarterly figures were released, leaving the European healthcare index far behind.
The company’s stock market value has increased dramatically since the start of the year. At the start of the year, a Biontech share cost less than 72 euros, Monday afternoon, the price rose to more than 340 euros, an increase of more than 350%. The market value has increased particularly rapidly since mid-July. Meanwhile, the debate over a possible third vaccination has intensified. Israel has been offering booster shots to people 60 and over for about a week – as the first country in the world and, as before, exclusively with Biontech’s vaccine.